Skip to content
DataLookout
Menu

NCT05937659

Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT

StatusWithdrawn
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: PRC Administrative Closure
    • Enrollment target: estimated 20 to confirmed 0
    • Site contact updated
  2. Notable Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site contact updated
  3. Notable Start date: May 15, 2026 to Sep 15, 2026v15
  4. Notable Primary and study completion pushed from Mar 15, 2027 to Oct 30, 2027
    • Start date: Mar 15, 2026 to May 15, 2026
    v14
  5. Notable Start date: Dec 15, 2025 to Mar 15, 2026v13
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Start date: Sep 15, 2025 to Dec 15, 2025v12
  2. Notable Start date: Jul 15, 2025 to Sep 15, 2025v11
  3. Notable Start date: May 15, 2025 to Jul 15, 2025v10
  4. Notable Primary and study completion dates: Mar 15, 2026 to Mar 15, 2027
    • Start date: Feb 15, 2025 to May 15, 2025
    v9
  5. Notable Primary and study completion dates: Mar 15, 2025 to Mar 15, 2026v8
  6. Notable Start date: Dec 15, 2024 to Feb 15, 2025v7
  7. Notable Start date: Nov 15, 2024 to Dec 15, 2024v6
  8. Notable Start date: Nov 15, 2023 to Nov 15, 2024v5
  9. Notable Start date: Sep 15, 2023 to Nov 15, 2023v4
  10. Notable Start date: Aug 15, 2023 to Sep 15, 2023v3
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

The rate of technology adoption
Timeframe: Up to 12 weeks

Secondary (2)

Provider perception of the utility
Subject perception of the utility

Arms and interventions

Biometric Data Collection

Adult subjects with cancer and prescribed concurrent systemic therapy and radiation therapy and enrolled in the study.

Sites

1 site in 1 country

  • Novant Health Cancer Institute Radiation OncologyWilmington, North Carolina, United States